Oncolytics Biotech’s (ONCY) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

Oncolytics Biotech Trading Down 2.7 %

Shares of ONCY opened at $0.92 on Thursday. The stock has a 50 day moving average of $0.99 and a 200 day moving average of $1.04. The company has a market capitalization of $71.18 million, a price-to-earnings ratio of -3.08 and a beta of 1.80. Oncolytics Biotech has a 12 month low of $0.85 and a 12 month high of $2.30.

Oncolytics Biotech (NASDAQ:ONCY) last announced its earnings results on Thursday, August 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. During the same period in the previous year, the business earned ($0.09) EPS. As a group, equities research analysts predict that Oncolytics Biotech will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 0.07% of Oncolytics Biotech at the end of the most recent quarter. 6.82% of the stock is owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.